Viewing nowPregabalin Capsule 50 mg (Pregabalin)
Pregabalin 50mg
Hard capsule · Prescription medication
Saehan Pharmaceutical Co., Ltd.

MFDS item code 201902604 · Approved 2019.04.25 · Insurance code 651301000
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication effectively treats peripheral and central neuropathic pain in adults. It is also used as an adjunct therapy for partial seizures in patients with epilepsy, helping to alleviate symptoms. Additionally, it aids in pain relief for fibromyalgia patients. This drug is used for various neurological disorders to improve the quality of life of patients.
This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Because this medicine is excreted mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of administration.’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, it may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of administration Based on current clinical experience, if this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment Because clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. This medicine is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after every 4 hours of hemodialysis. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as indicated in the dosing regimen. b: Supplemental dose refers to a dose administered once in addition. 6. Patients with hepatic impairment No dose adjustment is needed in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts and behaviors, so patients should immediately inform their healthcare provider if they experience mood changes or depression symptoms while taking it. Patients with allergies to this drug's components should not take it. Diabetic patients may need to adjust the dosage of their blood sugar control medications due to weight gain. In case of severe allergic reactions such as angioedema, the medication should be discontinued immediately, and medical advice should be sought. Elderly patients may experience dizziness or drowsiness while taking this medication, so caution is needed to avoid the risk of falls and accidents. This drug may cause temporary blurred vision or changes in vision, and patients should consult their healthcare provider if they experience these symptoms. Withdrawal symptoms such as insomnia, headache, and anxiety may occur upon discontinuation, so the dosage should be gradually reduced as per doctor’s instruction. Patients with a history of drug abuse may have a higher risk of abuse with this medication, and caution is needed during its use. Patients with reduced kidney function may require dosage adjustments. Patients with severe heart conditions should exercise caution when taking this medication, and if symptoms of heart failure occur, they should consult their healthcare provider immediately. Caution should be exercised when taking this drug in combination with other medications that have central nervous system depressant effects due to the risk of respiratory depression. Pregnant women should avoid this medication due to the risk of fetal malformations in early pregnancy, and women of childbearing age should use effective contraception. Breastfeeding women are advised to stop nursing or discontinue this medication as it can be passed into breast milk. Activities requiring attention, such as driving or operating machinery, should be avoided until dizziness or drowsiness subsides after taking this medication. In case of overdose, symptoms such as confusion, drowsiness, and seizures may occur, and immediate emergency treatment should be sought. This medication should be kept out of reach of children, and transferring it to another container could pose an accident risk.
Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, periorbital swelling, upper airway swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in eyesight, insomnia, headache, nausea, anxiety, diarrhea, influenza-like syndrome, restlessness, despondency, suicidal ideation, pain, seizures, hyperhidrosis, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, impaired respiratory function, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, decreased oral sensation, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweats, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, reduced urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, breast hypertrophy, peripheral edema, edema, gait abnormalities, falling, feeling intoxicated, altered sensation, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased potassium levels, increased creatinine, decreased white blood cell count, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, irritability, sense of well-being, decreased libido, depersonalization, sexual arousal disorder, restlessness, mood changes, emotional decline, emotional elevation, difficulty in finding appropriate terminology, hallucinations, abnormal dreams, increased libido, panic attacks, impulsivity, apathy, ataxia, coordination disorders, balance disturbances, amnesia, attention disorders, memory disorders, tremors, dysarthria, abnormal sensory perception, decreased sensation, sedation, somnolence, cognitive impairment, nystagmus, speech disorders, dystonic muscle spasms, decreased reflexes, movement disorders, psychomotor agitation, positional vertigo, hypersensitivity, burning sensation, activity tremors, syncope, confusion, hypokinesia, olfactory disturbances, loss of taste, writing difficulties, diplopia, vertigo, auditory hypersensitivity, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, keratitis, pulmonary edema, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, fatigue, delirium, paralysis (facial paralysis), affective disorder, drowsiness, confused state, agitation, restlessness, worsening of convulsions, sleep disorders, skin conditions, bloody stool, tinnitus, increased BUN, dysuria, ataxia, dysphasia, abnormal sensory perception, memory disorders, attention disorders
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture, and it is best to keep it at room temperature between 15 to 30 degrees Celsius.
Hard capsule consisting of a dark blue upper part and a white lower part filled with white or grayish-white crystalline powder
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 50mg
Hard capsule · Prescription medication
Saehan Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.